Find a Clinical Trial

ELATE

(ELATE) Essential Tremor: A Phase 2 Multicenter, Randomized, Doduble-blind, Placebo-controlled Study of BOTOX for the Treatment of Upper Limb Essential Tremor

18-80

Learn more

Ganaxolone in status epilepticus

A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of intravenous Ganaxolone in status epilepticus

18+

Learn more

BlueRock PD

A Multi-center, Noninterventional Study Evaluating Variability, Reliability, and Compliance for the Parkinson's Disease Diary

39-70

Learn more

OCEANIC-STROKE

A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA

18+

Learn more

Collagen Urine Assay

A Novel Urine assay to determine collagen levels in men with severe symptoms of bladder outlet obstruction

50-80

Learn more

Organogenesis Knee OA

A Phase 3 Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of Amniotic Suspension Allograft (ASA) in Patients with Osteoarthritis of the Knee

18+

Learn more

Gemini 1

A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis

18-55

Learn more

Hercules

A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis

18-60

Learn more

PERSEUS

A Phase 3, Randomized, Double-Blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants with Primary Progressive Multiple Sclerosis

18-55

Learn more

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)

A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)

18+

Learn more